Nadav Kidron net worth and biography

Nadav Kidron Biography and Net Worth

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.

He co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

He holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

What is Nadav Kidron's net worth?

The estimated net worth of Nadav Kidron is at least $277,200.00 as of March 16th, 2023. Mr. Kidron owns 126,000 shares of Oramed Pharmaceuticals stock worth more than $277,200 as of March 31st. This net worth estimate does not reflect any other assets that Mr. Kidron may own. Learn More about Nadav Kidron's net worth.

What is Nadav Kidron's salary?

As the CEO of Oramed Pharmaceuticals Inc., Mr. Kidron earned a total compensation package of $4,020,581.00 in 2021. Mr. Kidron earned a salary of $465,982.00, a bonus of $300,000.00, options awards of $876,693.00, and other compensation of $382,240.00. Learn More on Nadav Kidron's salary.

How do I contact Nadav Kidron?

The corporate mailing address for Mr. Kidron and other Oramed Pharmaceuticals executives is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. Oramed Pharmaceuticals can also be reached via phone at (844) 967-2633 and via email at [email protected] Learn More on Nadav Kidron's contact information.

Has Nadav Kidron been buying or selling shares of Oramed Pharmaceuticals?

During the last quarter, Nadav Kidron has bought $254,040.00 in Oramed Pharmaceuticals stock. Most recently, on Thursday, March 16th, Nadav Kidron bought 26,000 shares of Oramed Pharmaceuticals stock. The stock was acquired at an average cost of $2.04 per share, with a total value of $53,040.00. Following the completion of the transaction, the chief executive officer now directly owns 126,000 shares of the company's stock, valued at $257,040. Learn More on Nadav Kidron's trading history.

Who are Oramed Pharmaceuticals' active insiders?

Oramed Pharmaceuticals' insider roster includes Nadav Kidron (CEO), and Kevin Rakin (Director). Learn More on Oramed Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Oramed Pharmaceuticals?

During the last year, Oramed Pharmaceuticals insiders bought shares 3 times. They purchased a total of 146,000 shares worth more than $293,240.00. During the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 13,325 shares worth more than $167,228.75. The most recent insider tranaction occured on March, 16th when CEO Nadav Kidron bought 26,000 shares worth more than $53,040.00. Insiders at Oramed Pharmaceuticals own 6.9% of the company. Learn More about insider trades at Oramed Pharmaceuticals.

Information on this page was last updated on 3/16/2023.

Nadav Kidron Insider Trading History at Oramed Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2023Buy26,000$2.04$53,040.00126,000View SEC Filing Icon  
3/14/2023Buy100,000$2.01$201,000.00100,000View SEC Filing Icon  
8/9/2021Sell220,000$20.11$4,424,200.00648,573View SEC Filing Icon  
7/10/2018Sell61$5.98$364.78958,087View SEC Filing Icon  
5/12/2016Buy1,000$6.95$6,950.00957,448View SEC Filing Icon  
3/19/2015Buy2,600$3.88$10,088.00View SEC Filing Icon  
See Full Table

Nadav Kidron Buying and Selling Activity at Oramed Pharmaceuticals

This chart shows Nadav Kidron's buying and selling at Oramed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oramed Pharmaceuticals Company Overview

Oramed Pharmaceuticals logo
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
Read More

Today's Range

Now: $2.19
Low: $2.14
High: $2.21

50 Day Range

MA: $2.11
Low: $1.93
High: $2.23

2 Week Range

Now: $2.19
Low: $1.81
High: $13.73


150,110 shs

Average Volume

1,810,607 shs

Market Capitalization

$87.12 million

P/E Ratio


Dividend Yield